Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes #MDS with a TP53 Mutation | #leusm https://www.biospace.com/article/releases/aprea-therapeutics-receives-fda-breakthrough-therapy-designation-for-apr-246-in-combination-with-azacitidine-for-the-treatment-of-myelodysplastic-syndromes-mds-with-a-tp53-mutation/?TrackID=16 … #jobs
0 replies
11 proslijeđenih tweetova
25 korisnika označava da im se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.